Gastrectomy and chemotherapy with S-1 for gastric cancer in a patient with acquired immunodeficiency syndrome.
Total gastrectomy and chemotherapy with S-1 after surgery were performed in a 50-year-old woman with gastric cancer associated with acquired immunodeficiency syndrome (AIDS). She was given a diagnosis of gastric cancer at the lesser curvature of the body of the stomach, and distal gastrectomy was performed in December 2004. The postoperative course was eventful, with persistent high fever of unknown origin after surgery and infiltrative shadows in the bilateral lung fields showing on CT scan. Polymerase chain reaction (PCR) for pneumocystis carinii on bronchoscopy was positive, serum HIV antibody was positive, HIV-RNA was 2.2 × 10(5) copies/ml, and the serum CD4 lymphocyte level was 25/mm(3) on postoperative day 28. She was given a diagnosis of pneumocystis carinii with AIDS. Pneumocystis carinii and fever improved immediately when ST mixture and highly active antiretroviral therapy (HAART) were performed. After 3 months, the serum CD4 lymphocyte level was elevated to 125/mm(3), and she underwent total gastrectomy because cancer cells at the cut end of the resected stomach were positive microscopically. The postoperative course was uneventful, and she underwent adjuvant chemotherapy with S-1 because the serum CD4 lymphocyte level was 568/mm(3). S-1 therapy was continued for 2 years (each course consisting of 2 weeks of administration followed by 2 weeks off) while performing HAART and monitoring CD4 lymphocyte levels. No side effects such as decreases in white blood cell counts or CD4 lymphocyte levels were seen during S-1 therapy. She is alive and well without recurrence of gastric cancer 5 years after initial gastrectomy.
Suzuki
Ryuji
R
Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada, Shinjuku-ku, Tokyo 162-0054, Japan. sakuyama@ige.twmu.ac.jp
Ariizumi
Shunichi
S
Araida
Tatsuo
T
Hayashi
Kazuhiko
K
Yamamoto
Masakazu
M
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D016720:Pneumocystis Infections / Q000150:complications / Q000188:drug therapy; D045363:Pneumocystis carinii / Q000302:isolation & purification; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005641:Tegafur / Q000627:therapeutic use*; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid
Arch Surg. 2006 Dec;141(12):1238-45
17178967
Oncogene. 2003 Sep 29;22(42):6646-59
14528290
Jpn J Clin Oncol. 1989 Mar;19(1):75-8
2537909
N Engl J Med. 2007 Nov 1;357(18):1810-20
17978289
Rinsho Ketsueki. 1994 Sep;35(9):886-91
7967058
Int J STD AIDS. 2007 Jul;18(7):501-4
17623512
Am J Ophthalmol. 1990 Dec 15;110(6):707-9
2248343
Arch Surg. 1998 Jun;133(6):626-31
9637461
Gastric Cancer. 2000 Dec 27;3(3):151-155
11984729
Cutis. 1993 Sep;52(3):173-6
8243103
Curr Opin Infect Dis. 2006 Feb;19(1):14-9
16374212
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
1361652
Drugs Aging. 2002;19(9):647-69
12381235
Int J Cancer. 2008 Jul 1;123(1):187-94
18435450
J Surg Oncol. 2005 Jan 1;89(1):23-7
15612013